RWF_KTE-C19-102

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Study KTE-C19-102 is a phase 2, multicenter, open-label study evaluating the efficacy of KTE-C19 in subjects with Relapsed/Refractory MCL.

Inclusion Criteria:
• Pathologically confirmed MCL
• Up to 5 prior regimens for MCL. Prior therapy must have included: Anthracycline or bendamustine-containing chemotherapy and Anti-CD20 monoclonal antibody therapy and Ibrutinib
• Relapsed or refractory disease, defined by the following: Disease progression after last regimen, or Refractory disease is defined failure to achieve a PR or CR to the last regimen
• At least 1 measurable lesion according to the revised IWG Response Criteria for Malignant Lymphoma

Exclusion Criteria:
• History of malignancy other than nonmelanomatous skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years
• History of allogeneic stem cell transplantation
• Prior CD19 targeted therapy
Phase II
NCT02601313
Oncology
Hematologic
John Godwin, M.D.
Kite Pharma, Inc
Laurie Miller
  • Oncology and Hematology Care Eastside